News - Acadia Pharmaceuticals
Dec 19, 2024 · Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
News | Acadia Pharmaceuticals
Oct 9, 2024 · Read about the latest news and initiatives at Acadia Pharmaceuticals and find corporate assets, logos, and fact sheets.
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 …
Mar 11, 2024 · SAN DIEGO–(BUSINESS WIRE)–Mar. 11, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare ...
Nov 5, 2024 · SAN DIEGO–(BUSINESS WIRE)–Nov. 5, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of …
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE ...
Mar 10, 2023 · SAN DIEGO–(BUSINESS WIRE)–Mar. 10, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE ™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the ...
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 ...
Feb 27, 2024 · SAN DIEGO–(BUSINESS WIRE)–Feb. 27, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2023. “2023 was a transformational year for Acadia that positioned us for continued success in 2024 and beyond.
Acadia Pharmaceuticals Announces Exclusive License Agreement …
Nov 26, 2024 · SAN DIEGO–(BUSINESS WIRE)–Nov. 26, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABA A-α3 positive allosteric modulator. The first indication ...
Acadia Pharmaceuticals Announces Phase 3 Development …
Jun 13, 2023 · SAN DIEGO–(BUSINESS WIRE)–Jun. 13, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for the treatment of hyperphagia (a false and unrelenting state of starvation) in Prader-Willi syndrome (PWS).
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial …
Nov 6, 2024 · SAN DIEGO–(BUSINESS WIRE)–Nov. 6, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
Acadia Pharmaceuticals Announces Closing of Sale of Rare …
Dec 11, 2024 · SAN DIEGO–(BUSINESS WIRE)–Dec. 11, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses.